Title: TARGET – Real-World-Evidence study on the long-term benefits of
MCT®-associated pollen allergoid SCIT on AR and asthma
Short title: TARGET: Tyrosine-Allergoid – RWE in Germany –
Effectiveness in AIT
Author list: Christian Vogelberg1, Ludger
Klimek2, Silvia Kruppert3, Sven
Becker4
1Department of Pediatric Pneumology and Allergology,
University Hospital Carl Gustav Carus Dresden, Technical University
Dresden, Dresden, Germany; 2Center for Rhinology and
Allergy, Wiesbaden, Germany; 3IQVIA, Frankfurt,
Germany; 4Department of Otorhinolaryngology, Head and
Neck Surgery, University of Tübingen, Tübingen, Germany
ORCID:
Christian Vogelberg: https://orcid.org/ 0000-0002-4881-8368
Ludger Klimek: https://orcid.org/0000-0002-2455-0192
Silvia Kruppert: https://orcid.org/0000-0002-5953-5750
Sven Becker: https://orcid.org/0000-0003-1972-3797
Abstract:
Background: Allergen immunotherapy (AIT) may have a long-term disease
modifying effect. The aim of this study is to demonstrate the long-term
benefit of MCT®-associated
allergoid pollen SCIT (MCT®-associated -AIT) on allergic rhinitis (AR)
and asthma in clinical practice.
Methods: In this retrospective Real-World-Evidence (RWE) study the
impact of AIT on the progression of AR and onset of need for asthma
medication was analyzed using a German longitudinal database. Anonymized
prescription data of AR patients and exactly matched control patients
aged from 5-65 years were analyzed.
Results: Significantly less patients treated with MCT®-associated-AIT
did receive prescriptions for symptomatic AR medication in the follow up
period vs. control group (OR: 0.27; p < 0.001). Further,
significantly less asthmatic patients under MCT®-associated-AIT did
receive prescriptions for asthma medications (OR: 0.48; p = 0.004). In
addition, the prescriptions of AR and asthma medication for
MCT®-associated-AIT patients were significantly reduced in the follow-up
vs. baseline and control group (24.2% and 35.6%, respectively,
p < 0.001).The probability of asthma medication onset in
non-asthmatic patients during follow-up was significantly reduced for
AIT patients compared to controls (OR: 0.77, p = 0.001). All endpoints
were significant for children/adolescents and adults in the individual
analyses.
Conclusions: This study gives evidence for long-term benefits up to 9.5
years of MCT®-associated-AIT on the need for AR and new-onset asthma
medication in AR patients and asthma medication in asthmatics in an RWE
setting.
Keywords: AIT, allergic rhinitis, allergoids, asthma occurrence,
asthma progression